MedinCell S.A. (MEDCL.PA)
- Previous Close
14.93 - Open
14.93 - Bid --
- Ask --
- Day's Range
14.93 - 15.49 - 52 Week Range
12.00 - 19.00 - Volume
66,283 - Avg. Volume
71,097 - Market Cap (intraday)
506.259M - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-1.09 - Earnings Date Jun 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.40
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
www.medincell.comRecent News: MEDCL.PA
View MorePerformance Overview: MEDCL.PA
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDCL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDCL.PA
View MoreValuation Measures
Market Cap
506.26M
Enterprise Value
527.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
41.18
Price/Book (mrq)
--
Enterprise Value/Revenue
48.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-238.24%
Return on Assets (ttm)
-22.38%
Return on Equity (ttm)
--
Revenue (ttm)
13.2M
Net Income Avi to Common (ttm)
-31.45M
Diluted EPS (ttm)
-1.09
Balance Sheet and Cash Flow
Total Cash (mrq)
38.85M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
6.99M